Beam cuts 20% of staff, looks to part­ner on base-edit­ed CAR-T one month af­ter dos­ing first pa­tient

Last year
R&D
Cell/Gene Tx

Chan Zucker­berg’s new cen­ter in New York; En­deav­or buys rights to ADC; Basilea ac­quires an­ti­fun­gal

Last year
News Briefing

Why a Wal­greens ex­ec is bet­ting that re­tail phar­ma­cies can be a force to change how health­care’s paid for and ...

Last year
Health Tech

Af­ter years of hype, the first AI-de­signed drugs fall short in the clin­ic

Last year
AI
In Focus

Illi­nois man ac­cused of in­sid­er trad­ing af­ter mak­ing near­ly $100K on Pfiz­er-Ar­ray buy­out

Last year
Law

Roche makes four pipeline changes on back of tri­al fail­ures, but sees path ahead for three ther­a­pies

Last year
Pharma

Pfiz­er sets Paxlovid price at $1,390 for five-day course

Last year
Pharma
Coronavirus

Emer­gent re­cruits NFL Hall of Famer for Nar­can opi­oid over­dose cam­paign

Last year
Pharma
Marketing

EMA looks in­to fal­si­fied Ozem­pic with Ger­man and Aus­tri­an ori­gins

Last year
FDA+

Pfiz­er agrees to $2M set­tle­ment deal over gen­der dis­crim­i­na­tion al­le­ga­tions

Last year
Pharma

NIH di­rec­tor nom­i­nee Bertag­nol­li skirts drug pric­ing ques­tions at con­fir­ma­tion hear­ing

Last year
People
Pharma

FDA al­lows first piv­otal tri­al of an in vi­vo gene edit­ing treat­ment from In­tel­lia

Last year
Cell/Gene Tx
FDA+

Lig­and pays $30M up­front in roy­al­ty deal; Ac­tym ex­tends its Se­ries A; Gero rais­es $6M

Last year
News Briefing

Syn­cona eyes buy­out of gene ther­a­py biotech Free­line af­ter ear­ly da­ta in two Gauch­er pa­tients

Last year
Deals
Cell/Gene Tx

Big Phar­mas part­ner with HBCU, with aim to cre­ate the largest African an­ces­try ge­nomics data­base

Last year
R&D
Pharma

Women’s chron­ic care start­up Al­lara rais­es $10M to ex­pand na­tion­wide

Last year
Health Tech

Brain­Storm with­draws ALS drug ap­pli­ca­tion af­ter neg­a­tive ad­comm vote

Last year
FDA+

Med­ic­aid start­up Way­mark rais­es $42M in a round led by Lux Cap­i­tal

Last year
Health Tech

Ora­sis gains FDA ap­proval for pres­by­opia eye drops, fol­low­ing in Ab­b­Vie’s foot­steps

Last year
Pharma
FDA+

Klick’s lat­est health tech us­es a per­son’s voice and ar­ti­fi­cial in­tel­li­gence to de­tect di­a­betes

Last year
Marketing

UCB wins FDA ap­provals in plaque pso­ri­a­sis and gMG, un­lock­ing block­buster op­por­tu­ni­ties

Last year
Pharma

Takeda's stem cell ther­a­py flunks PhI­II test study­ing the drug in Crohn's dis­ease

Last year
R&D

Carl Ic­ahn sues Il­lu­mi­na board mem­bers over Grail ac­qui­si­tion

Last year
Diagnostics
Law

FDA ap­proves new in­di­ca­tion for Arde­lyx's tena­panor for serum phos­pho­rus con­trol

Last year
Pharma
FDA+
First page Previous page 261262263264265266267 Next page Last page
A service from the Financial Times